The Turkish Competition Board grants individual exemption to an exclusive distribution agreement (GlaxoSmithKline / Pfizer)

In an interesting decision on 20 June 2008, the Turkish Competition Board (TCB) has granted an individual exemption to an exclusive distribution agreement between GlaxoSmithKline Pharmaceuticals Co. and Pfizer Pharmaceuticals Ltd after refusing to grant negative clearance to the agreement under the Vertical Agreements Block Exemption Communiqué (2002/2). The subject matter of the decision was the request for negative clearance of an exclusive distribution agreement GlaxoSmithKline entered into with Pfizer regarding the distribution and promotion of ‘Requip' in the Republic of Turkey, a drug produced by GlaxoSmithKline against Parkinson's disease and Restless Leg Syndrome (RLS). The relevant market of the case at hand was defined as the market for ‘n° 4A class anti-Parkinson's disease

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • University of Leeds

Quotation

Pinar Akman, The Turkish Competition Board grants individual exemption to an exclusive distribution agreement (GlaxoSmithKline / Pfizer), 20 June 2008, e-Competitions Bulletin June 2008, Art. N° 22336

Visites 6112

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues